Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1621-1640 of 2,251 trials

Myelodysplastic Syndromes: Oral ASTX030 vs. Subcutaneous Azacitidine

We are studying a new oral treatment for patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. The trial aims to evaluate its safety and how it compares to the standard subcutaneous treatment.

Chronic Myelomonocytic LeukaemiaAcute Myeloid LeukaemiaMyelodysplastic Syndrome>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesHematology

Exercise and Statin Use in Advanced Cancer Treatment

We are studying whether supervised exercise and atorvastatin can improve cancer treatment outcomes for patients with advanced breast, renal, ovarian, and prostate cancers. We also want to understand how these interventions affect patients' quality of life and experiences during treatment.

Metastatic Breast, Ovarian, Prostate, and Kidney Cancer≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncologyUrology

Dupuytren's Contracture: Comparing Treatment Options

We are studying three different treatments for Dupuytren's contracture to see which one works best and is most cost-effective. This trial includes patients with mild to moderate cases and will track outcomes over several years.

Dupuytren's Contracture>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesDermatologyOrthopedics and Traumatology

Solid Tumors: Genetically Modified T-Cell Therapy

We are studying a new treatment using modified T-cells from patients to target specific tumor markers in solid tumors. The trial will help us understand its safety and effectiveness, both alone and with another medication.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Rabies Vaccine: Pain and Usability Study for Kids

We are exploring how different injection methods affect pain and anxiety in children aged 4 to 14 receiving a rabies vaccine. Parents will also share their observations about their child's experience.

Rabies Pre-Exposure Prophylaxis3-6 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesPediatrics

Liver Cancer: Immunotherapy and Radioactive Treatment Study

We are studying the effects of two immunotherapy drugs combined with a special treatment for liver cancer. This trial aims to see if this combination improves survival and quality of life for patients with non-resectable liver cancer.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHepatologyOncology

Advanced Breast Cancer: The p53 Trial

We are testing a chemotherapy treatment for patients with advanced breast cancer that has TP53 mutations. The goal is to see how well it works and to understand the safety and response of different mutation types.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Recurrent Grade-4 Glioma: Bortezomib and Temozolomide Study

We are studying the safety and effectiveness of combining Bortezomib with Temozolomide for patients with recurrent grade-4 glioma. This research may help improve treatment options for this challenging condition.

Malignant Glioma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Colorectal Surgery: Cefoxitin Administration Study

We are comparing two ways of giving cefoxitin to prevent infections after colorectal surgery. This study aims to find out if a continuous infusion is better than the standard method for reducing complications.

Colorectal Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInfectious DiseasesInternal MedicineOrthopedics and Traumatology

CAR T-Cell Therapy for Blood Cancers

We are testing a new CAR T-cell treatment for patients with relapsed or refractory CD19-positive blood cancers. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Ovarian Cancer: ZN-c3 and Niraparib Study

We are studying the safety and effectiveness of a new drug, ZN-c3, alone and with niraparib for patients with platinum-resistant ovarian cancer. This trial aims to find better treatment options for those who have limited choices.

Recurrent Ovarian Cancer>2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cemiplimab for High-Risk Skin Cancer

We are studying whether the immunotherapy Cemiplimab can help prevent cancer recurrence in patients with high-risk stage III/IV skin cancer who can undergo surgery.

Cutaneous Squamous Cell CarcinomaSurgically Resectable, High Risk Stage III/IV Cutaneous Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDermatologyOncology

Advanced Pancreatic Cancer: Gemcitabine and Nab-Paclitaxel Study

We are studying whether switching to a new treatment after initial chemotherapy helps patients with advanced pancreatic cancer live longer and feel better compared to continuing their current treatment.

Advanced Pancreatic Cancer≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Desmoid Tumors: Nirogacestat Study for Women

We are studying how Nirogacestat affects ovarian function in adult premenopausal women with desmoid tumors. The trial aims to understand any ovarian toxicity and the overall safety of the treatment.

Desmoid Tumors (Aggressive Fibromatosis)1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

HPV Vaccine Study for Women with HPV 16/18

We are studying how the 9vHPV vaccine affects the infectivity of HPV in women who are positive for HPV types 16 and/or 18. The goal is to see if vaccination reduces the virus in cervical, anal, urine, vulvar, and oral samples.

Human Papillomavirus Infection>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Kidney Transplant: IVIG for BKV Prevention

We are studying whether intravenous immunoglobulins can help prevent BKV viremia in kidney transplant recipients with low antibody levels. This research aims to improve outcomes for patients at risk of BKV-related complications.

Kidney Transplant and BKV Infection>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesNephrology

Ewing Sarcoma: Dinutuximab Beta with Chemotherapy

We are studying a new treatment combining dinutuximab beta with standard chemotherapy for patients with GD2-positive Ewing sarcoma. The goal is to find the best dose and assess how well it works in improving patient outcomes.

Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

New Method for Umbilical Vein Catheterization in Newborns

We are studying a new technique for umbilical vein catheterization to see if it helps newborns in circulatory arrest receive faster and more effective resuscitation. This trial compares the new method with standard practices in the delivery room.

Cardiorespiratory Arrest at Birth in Full-Term Newborns≤3 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePediatrics

Myelofibrosis: Roginolisib with Ruxolitinib

We are studying the safety and tolerability of roginolisib combined with ruxolitinib for patients with myelofibrosis who haven't responded to other treatments. The trial also looks at symptom improvement and changes in spleen size.

MyelofibrosisSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Fecal Incontinence: Botulinum Toxin Injections

We are studying how botulinum toxin injections may improve rectal movement in patients with fecal incontinence. The trial will also look at the treatment's effectiveness, quality of life, and tolerance after one month.

Fecal Incontinence>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine